- 1Centre for the Studies of Asphyxia and Resuscitation, Royal Alexandra Hospital, Edmonton, AB, Canada
- 2Department of Pediatrics, University of Alberta, Edmonton, AB, Canada
- 3Women and Children’s Health Research Institute (WCHRI), University of Alberta, Edmonton, AB, Canada
- 4Department of Neonatology, The Royal Women’s Hospital, University of Melbourne, Melbourne, VIC, Australia
- 5The Ritchie Centre, Department of Paediatrics, Monash University, Hudson Institute of Medical Research, Melbourne, VIC, Australia
- 6Department of Paediatrics, University of Toronto, Toronto, ON, Canada
- 7Department of Pediatrics, McMaster University, Hamilton, ON, Canada
Background: The rapid establishment of gas exchange after birth is vital for survival and long-term health. When newborn infants fail to initiate spontaneous breathing, positive pressure ventilation (PPV) is the cornerstone of respiratory support immediately after birth. The aim of PPV is to inflate the lungs, create a functional residual capacity, deliver an adequate tidal volume (VT), facilitate gas exchange, and stimulate breathing, without causing lung or brain injury. In the delivery room, PPV is routinely provided via a pressure-limited device (called a T-Piece resuscitator), where an arbitrary peak inflation pressure (PIP) is set, with the assumption an adequate and safe VT will be delivered. An alternative approach would be using a ventilator to deliver volume-targeted ventilation (VTV), whereby the PIP is adjusted to target a set VT measured by an inline flow sensor. While several trials have evaluated the use of respiratory function monitors to adjust the delivered VT during PPV, no trial has compared PPV with VTV-PPV in the delivery room.
Methods: A randomized trial of VTV-PPV vs. PPV during neonatal resuscitation in preterm infants at birth to assess feasibility of a definitive trial for the intervention. Preterm infants born between 230/7 to 286/7 weeks' gestation will be eligible. Patients will be randomized to either the intervention (VTV-PPV) or the comparator (PPV) during respiratory support in the delivery room. The sample size will be 50 preterm infants. The primary outcome will be percentage of eligible participants (=infants requiring PPV) who have the intervention performed correctly without protocol deviation (=cross over to control group when randomized to VTV-group). Secondary outcomes will include neonatal morbidities (e.g., death, severe brain injury, bronchopulmonary dysplasia; and severe retinopathy of prematurity).
Discussion: The VOLT-trial aims to assess feasibility of VTV-PPV and will address gaps in the evidence regarding the optimal approach to the establishment of ventilation in the delivery room. We aim to use to results of this trial to inform the design of a large multi-centre trial.
Study Protocol Registration: https://clinicaltrials.gov/study/NCT05144724, identifier NCT05144724.
Introduction
Background and rationale
Limitations of current positive pressure ventilation practices in the delivery room
When newborn infants fail to initiate spontaneous breathing at birth, positive pressure ventilation (PPV) remains the cornerstone of respiratory support immediately (1–3). The purpose of PPV is to inflate and create functional residual capacity in the lung, deliver an adequate tidal volume (VT), facilitate gas exchange, and stimulate breathing, all while minimizing lung and brain injury (4). Positive pressure ventilation (PPV) in the delivery room is usually provided via a face mask with a T-piece resuscitator, where peak inflation pressure (PIP) is selected without measuring the actual tidal volume (VT) delivered. Instead, adequacy is judged by heart rate and chest wall movement, though studies show healthcare providers often cannot reliably assess chest wall movement (5–7).
Tidal volume variability and Its link to lung and brain injury at birth
Preterm infants are susceptible to ventilation-induced lung injury, as the volume difference between functional residual capacity and total lung capacity is small in this population (8). Delivery room studies reported that VT during mask PPV ranges between 0 and 31 mL/kg (6, 9–13). This is concerning as animal studies demonstrated that lung injury was predominantly caused by high VT ventilation (>8 mL/kg) and if VT was controlled to avoid lung over-distention, little or no injury occurred (14–22).
Similarly, studies in preterm lambs reported that PPV with VT >8 mL/kg causes brain injury through increased inflammation, hemodynamic instability, and oxidative stress (17–19). Polglase et al. showed that preterm lambs ventilated with higher VT (10–12 mL/kg) for the first 15 min after birth had highly variable cerebral oxygenation, as measured by near-infrared spectroscopy (NIRS), compared to preterm lambs ventilated with a protective strategy (VT < 8 mL/kg) (19). Disruption of the blood-brain barrier was observed in 60% of preterm lambs ventilated with high VT, as evidenced by vascular protein extravasation, but was not observed in preterm lambs ventilated with a protective strategy. These preclinical findings are supported by observational studies in the delivery room, which reported a four-fold increase in rates of severe intraventricular hemorrhage (IVH) in preterm infants (<29 weeks' gestation) when VT >6 mL/kg was delivered during PPV (23, 24). Therefore, approached which could improve VT delivery might reduce lung and brain injury.
Adjusting tidal volume to protect the preterm lung and brain
Randomized trials in the delivery room utilizing a Respiratory Function Monitor (RFM) during PPV, which allows the resuscitator to target VT, has been associated with a lower rate of excessive (>8 mL/kg) VT delivery (9–11). A systematic review of randomized trials comparing RFM visible vs. masked demonstrated confirmed that the proportion of infants receiving VT >8 mL/kg can be reduced with an RFM visible (25). However, rates of bronchopulmonary dysplasia were unchanged in all trials. Interestingly, brain injury (defined as any IVH and/or periventricular leukomalacia) can be reduced by 35% and any grade IVH by 32% with an RFM visible (25). Unfortunately, none of the randomized trials was powered to examine differences in brain injury (only reported as secondary outcomes), and therefore these results might have only occurred by chance.
Neonatologists are increasingly careful in the neonatal intensive care unit (NICU) to apply ventilation strategies that are gentle to the lungs (26, 27). Volume-targeted ventilation (VTV), where ventilators algorithmically adjust PIPs to target a set VT as detected through in an inline flow sensor, is routinely used in the NICU (26–28). A meta-analysis of VTV in the NICU showed a reduction in a number of adverse clinical endpoints, including (i) the incidence of pneumothorax (typical RR [95%CI] 0.46 [0.25–0.84], numbers needed to treat [95%CI] 17 [10–100]), (ii) hypocarbia (typical RR [95%CI] 0.56 [0.33–0.96], numbers needed to treat [95%CI] 4 [2–25]), (iii) combined outcome of death or bronchopulmonary dysplasia (typical RR [95%CI] 0.73 [0.57–0.93], numbers needed to treat [95%CI] 8 [5–33]), and (iv) the combined outcome of periventricular leukomalacia (PVL) or grade 3–4 IVH (typical RR [95%CI] 0.48 [0.28–0.84], numbers needed to treat [95%CI] 11 [7–50]) (27). However, despite the general acceptance of VTV in the NICU, clinicians appear less aware that the same gentle approach should be applied to PPV in the delivery room to reduce lung and brain injury immediately after birth [36,43].
Unanswered question: does VTV improve outcomes compared to PPV in the delivery room?
Therefore, alternate methods of providing tight VT control during PPV in the delivery room resuscitation of preterm infants is needed, given the complex interaction of mask leak, lung compliance, PIP, and resuscitator skill. Using VTV immediately after birth would provide continuity from the delivery room into the NICU. Tracy et al. compared mask PPV with a T-Piece or VTV during simulated neonatal resuscitation and reported a lower coefficient of variations and lower VT delivery with ventilator driven VTV compared PPV with a T-Piece (29). Similarly, Jain et al. compared VTV via a mechanical ventilator to manual T-Piece PPV and reported improved volume targeting at different compliance settings and a reduction in mask leak during simulated mask ventilation (30). These studies suggest that VTV is feasible at least during animal or simulated neonatal resuscitation. Furthermore, Menakaya et al. compared VTV with a PPV using a Flow-Inflating bag and reported that preterm infants be safely and effectively resuscitated using a ventilator (31). However, no study has compared VTV with T-Piece resuscitator during neonatal resuscitation of preterm infants in the delivery room. Thus, a clinical trial using VTV in the delivery room is urgently needed to determine if (a) this method can be feasibly used in the delivery room and (b) can potentially improve outcomes by reducing bronchopulmonary dysplasia and brain injury in preterm infants.
Objectives
Primary objective
To determine feasibility and safety of a trial comparing VTV-PPV to PPV in extremely preterm infants.
Secondary objectives
To evaluate clinical outcomes and HCP experience of the VTV-PPV.
Primary research question
Population: In preterm infants born at 230–286 weeks' gestation is a trial of Intervention: mask ventilation using a mechanical ventilator (VTV-PPV) Comparison: compared to mask ventilation using a T-Piece Resuscitator (PPV) Outcome: feasible during mask ventilation in the delivery room, which will be assessed by percentage of eligible participants (=infants requiring PPV) randomized to the VTV group and receive the allocated intervention without protocol deviation (i.e., without crossover to the control group) Timeline: during the first 10 min after birth?
Secondary research questions
1. In preterm infants born at 230–286 weeks of gestation, does mask ventilation using a mechanical ventilator compared to mask ventilation using a T-Piece Resuscitator reduce neonatal morbidities (severe brain injury, bronchopulmonary dysplasia; and severe retinopathy of prematurity) and reduce the number of infants requiring intubation in the delivery room by transitioning more successfully to CPAP.
2. What qualitative feedback do HCPs have on the experience of using VTV-PPV in the delivery room?
3. How does VTV-PPV compared with PPV affect subjective workload reported by HCPs performing mask ventilation?
Trial design
A single centre randomized controlled trial.
Methods: participants, interventions, outcomes
Study setting
Royal Alexandra Hospital, Edmonton, Canada, a tertiary perinatal center admitting ∼140 infants born between 23+0 to 28+6 weeks' gestation annually. The trial is registered on clinicaltrials.gov (https://clinicaltrials.gov/study/NCT05144724) (Table 1).
Eligibility criteria
Inclusion criteria (all must be satisfied)
- Born between 230/7 to 286/7 weeks' gestation based on best obstetrical estimates
- Considered suitable for full resuscitation, i.e., no parental request or antenatal decision to forego resuscitation
- Deferred parental consent post-intervention
Exclusion criteria
- Major congenital or chromosomal malformation
- Conditions that might have an adverse effect on breathing or ventilation (e.g., high risk for lung hypoplasia, congenital diaphragmatic hernia)
- Antenatally detected congenital heart disease requiring intervention in the neonatal period
- Antenatally diagnosed Hydrops requiring intervention in the neonatal period
- Neonatal resuscitation initiated before NICU team arrival
- Infants who are born outside of study center and transported to center after delivery
Consent or assent: who will take informed consent?
Informed parental/guardian consent will be obtained after the study intervention for ongoing data collection. The consent approach of obtaining individual consent after birth for data inclusion in the trial, will strengthen the number being recruited. Furthermore, this approach has been reviewed and approved by our local human ethics review board and is supported by the local Neonatal Family Advisory Care Team. For this important study to be feasible, and enroll a representative sample, an informed consent obtained after the study intervention for ongoing data is important, as obtaining consent prior to delivery can be difficult (32, 33). Guidelines for this approach as laid down by Tri-Council Policy Statement state that any study wishes to use deferred consent needs (34):
a) “A serious threat to the prospective participant requires immediate intervention.” Infants participating in this trial will require respiratory support, which in most cases was unforeseen prior to delivery; hence these infants will all need PPV and using mask ventilation will be therapeutic. Although the pressure limited PPV method (PPV group) is the routinely used method at the participating site, it would not be feasible for a neonatal resuscitation study to ask permission prior to delivery from every parent delivering within the participating site.
b) “either no standard efficacious care exists or the research offers a realistic possibility of direct benefit to the participant in comparison with standard care.” The currently used approach in the delivery room is pressure limited PPV. However, in the NICU, VTV is standard of care for providing mechanical ventilation, not for resuscitation on NICU. The available animal evidence and limited neonatal data suggest that the interventional approach has the potential to improve standards of care.
c) “either the risk is not greater than that involved in standard efficacious care, or it is clearly justified by the prospect for direct benefits to the participant.” Resuscitation is therapeutic and the currently available evidence suggest that the interventional approach (VTV-PPV group) has no higher risk of harm compared to the current standard of care (PPV group). Furthermore, the intervention approach is routine standard practice in the NICU, and has been shown to decrease combined outcomes of death/bronchopulmonary dysplasia and brain injury.
d) “the prospective participant is unconscious or lacks capacity to understand the risks, methods and purposes of the research project.” A person in labor cannot give a valid informed consent to a research study. Thus, the parents will be informed as soon as possible after stabilization of the infant about the study and asked to consent to the use of data that have been collected on their child.
e) “third party authorization cannot be secured in sufficient time, despite diligent and documented efforts to do so;” The parents will be informed as soon as possible after birth about the study and asked to consent to the use of data that have been collected on their child.
f) “No relevant prior directive by the participant is known to exist.”
g) There is an increasing use of the deferred consent approach within delivery room research. The steering committee of this application has ample experience with using this approach during neonatal resuscitation studies.
Consent or assent: ancillary studies
Parents of participating infants will be asked if they agree to use of their data should they choose to withdraw from the trial. Participants will also be asked for permission for the research team to share relevant data with people from the Universities taking part in the research where relevant. This trial does not involve collecting biological specimens for storage.
Interventions
Choice of comparators
In the delivery room, PPV is routinely provided via a T-Piece resuscitator, where a PIP is arbitrarily chosen, with the assumption it will deliver an adequate VT. However, the delivered VT is not measured and therefore PIP is not adjusted to optimize VT delivery. While a lung-protective strategy must start immediately after birth, this has not been studied in detail. Lung compliance and the corresponding PIP needed to deliver an appropriate VT vary between infants depending on gestational age, disease state and delivery mode (C-section vs. vaginal). In addition, the optimal PIP and VT for an individual infant change in the first minutes after birth as lung fluid is cleared and the lung aerated. Therefore, relying on a fixed PIP and subjective assessment of chest rise may result in harm by either under- or over-ventilation. It may be beneficial to measure and adjust the VT delivered during PPV in the minutes after birth, especially in very preterm infants at the greatest risk of lung and brain injury. Delivery room studies reported that VT during PPV ranges between 0 and 31 mL/kg, which is concerning as animal studies reported that lung injury was predominantly caused by high VT ventilation (>8 mL/kg). This led to the utilization of RFMs during PPV to target VT. Three trials compared an RFM visible to adjust the delivered VT to RFM masked, which resulted in a reduction of VT >8 mL/kg being delivered, but failed to reduce rates of bronchopulmonary dysplasia. Therefore, alternate methods of providing tight VT control during PPV in the delivery room resuscitation of preterm infants is needed. In the NICU, VTV ventilators which algorithmically adjust PIPs to target a set VT are routinely used. A meta-analysis of trials comparing VTV with pressure guided ventilation in the NICU showed a reduction in pneumothorax, combined outcome of death or bronchopulmonary dysplasia, combined outcome of PVL or grade 3–4 IVH. However, despite the general acceptance of VTV in the NICU, this approach is not used in the delivery room to reduce lung and brain injury immediately after birth. The trials will compare VTV-PPV with PPV during respiratory support immediately after birth to assess the feasibility of VTV-PVV.
Intervention description
Treatment arms
PPV group
The clinical team will proceed through all steps of the neonatal resuscitation algorithm, as per current neonatal resuscitation guideline (1–3) and local hospital policy (standard hospital practice guideline). Mask ventilation in the delivery room will be provided as per local hospital policy (standard hospital practice guideline). At the Royal Alexandra Hospital, mask ventilation is delivered with a T-piece device with initial settings of PIP of 24 cmH2O, a peak expiratory pressure PEEP of 6 cmH2O, a max PIP of 40 cmH2O and a gas flow rate of 8–10 L/min. Resuscitators are trained to use a ventilation rate of 40–60 inflations/min. The clinical team will determine if/when ventilation pressures (both PEEP and PIP) should be increased, as per local hospital policy (standard hospital practice guideline), using clinical assessments (heart rate, oxygen saturation, auscultation, chest raise) (Figure 1).
VTV-PPV group
Initial ventilation settings for VTV-PPV will be a VT of 5 mL/kg, a ventilation rate of 50 inflations/min, a maximum PIP of 40 cmH2O, and a PEEP of 6 cmH2O. For VTV-PPV, a size 9.0 endotracheal tube connector will be inserted into the facemask to allow secure attachment of the flow sensor and ventilator circuit. Ventilation will be delivered using PC-CMV with Volume Guarantee, beginning at 5 mL/kg and adjustable up to 6 mL/kg if required. The trigger sensitivity will be set at 0.2 L/min to enable infant-triggered breaths, and the inspiratory time will be set at 0.3 s, with the option to increase to 0.5 s based on clinical response. To minimize leak, clinicians will use a two-hand mask-hold technique, as the ventilator tubing is heavier than a T-piece and may otherwise create downward pull. The clinical team will proceed through all steps of the neonatal resuscitation algorithm, as per current neonatal resuscitation guidelines (1–3) and local hospital policy but will replace standard pressure-limited PPV with VTV-PPV in the intervention group. The clinical team will determine if and when VT, ventilation rate, and/or PEEP should be increased, using clinical assessments (heart rate, oxygen saturation, auscultation, chest rise). In addition, the clinical team will be trained to troubleshoot ventilator alarms such as low minute ventilation (e.g., airway obstruction) and disconnect alarms (e.g., mask leak) (Figure 1). No CO2 monitoring (end-tidal or transcutaneous) will be used due to feasibility limitations in the delivery room.
Duration of treatment period
The study intervention will be applied for the first 10 min after birth.
Criteria for discontinuing or modifying allocated interventions
In any cases where the resuscitation team believes, that VTV-PPV is not working, the resuscitation team can revert to standard hospital practice guideline of administering PPV using a T-Piece resuscitator at any time.
If HR <60 at any time despite 30 s of effective ventilation, the resuscitation guidelines state to use an alternate airway and start chest compression. At that time, the VTV-PPV approach must be abandoned and a T-Piece must be used.
Strategies to improve adherence to interventions
Training logs and continuing engagement during daily clinical huddles to remind about the study.
Relevant concomitant care permitted or prohibited during the trial
Other than providing PPV with either a ventilator (intervention) or a T-Piece (standard of care), all delivery room interventions will follow the center's local hospital policy (standard hospital practice guideline) and the current neonatal resuscitation guidelines (1–3).
Provisions for post-trial care
Care during the primary hospitalization will adhere to local practice guidelines.
Outcomes
Primary outcome
Percentage of eligible participants (=infants requiring PPV) who have the intervention performed correctly without protocol deviation (=cross over to control group when randomized to VTV-group).
Secondary outcomes
Secondary outcomes include:
1. All-cause in-hospital mortality
2. Severe brain injury on cranial ultrasound: Severe grade 3 and 4 intraventricular or intraparenchymal hemorrhage according to Papile (35), periventricular leukomalacia, or ventriculomegaly based on neuroimaging studies (timing and frequency of imaging based on local site practices)
3. Severe retinopathy of prematurity (stage 3 or higher) as defined in the International Classification of ROP, and/or ROP treated with laser, cryotherapy, or intraocular injection therapy (36)
4. Bronchopulmonary dysplasia at 36 weeks corrected age and at 40 weeks corrected age, defined as receiving any supplemental oxygen or any form of respiratory support (including invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, nasal intermittent positive pressure ventilation, or high-flow nasal canula)
5. Total duration of mechanical ventilation via an endotracheal tube in days
6. Discharge home on oxygen
7. Duration of any respiratory support (invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, nasal intermittent positive pressure ventilation, or non-invasive neural assist ventilation or non-invasive high frequency ventilation, or high-flow nasal cannula) in days
8. Duration of supplemental oxygen in days
9. Length of hospital stay in days
10. Rate of intubation in the delivery room
11. Rate of chest compression in the delivery room
12. Rate of pneumothorax (diagnosed by chest x-ray or lung ultrasound) and interventions (e.g., needle drainage or chest drain)
13. Necrotizing enterocolitis, Modified Bell's criteria stage 2 or greater (37)
14. Duration of positive pressure ventilation at birth (within the first 10 min)
15. Resuscitators subjective workload performing mask ventilation, as evaluated by Surgery Task Load Index (SURG-TLX)-questionnaire.
16. Resuscitators qualitative feedback on using VTV-PPV in the delivery room, provided through free text responses.
Participant timeline
Sample size
This will be a trial to assess the feasibility of VTV-PPV in the delivery room. Our primary outcome will assess the percentage of eligible participants (=infants requiring PPV) who have the intervention performed correctly without protocol deviation (=cross over to control group when randomized to VTV-group). We aim to recruit a sample of 50 infants (25 per arm) randomized 1:1 to VTV-PPV or PPV. The proposed sample size should be reached within 24 months. This study will be an initial trial for a large multi-center trial.
Recruitment
The study will be carried out at the Royal Alexandra Hospital, Edmonton, Canada, a tertiary perinatal center with ∼6,000 deliveries annually admitting ∼140 infants born between 23+0 to 28+6 weeks' gestation annually. Approximately 60% of babies born between 23 and 28 weeks' gestation require PPV at birth. The study site has a long history of conducting randomized trials and has the proven capability of enrolling the required number of infants. The number of infants being recruited will be 50, as per sample size. The overall recruitment period is a maximum of 24 months. There will be 50 infants recruited in Canada.
Assignment of interventions
Allocation
Sequence generation
The Biostatistics Unit at Women and Children's Health Research Institute (WCHRI), University of Alberta, Edmonton, Canada, will prepare the randomization schedule. Before trial initiation, a statistician will generate the 1:1 allocation sequence with computer-generated random numbers, which a second statistician will independently validate.
Concealment mechanism
The site's allocation sequence is password-protected, with access restricted to the independent statistician.
Implementation
Before the start of the trial, the statistician will use computer-generated random numbers to prepare the allocation sequence by producing the codes and allocation table. Clinical staff attending neonatal deliveries will open an envelope with the group assignment and will enroll participants.
Assignment of interventions: blinding
Who will be blinded
Blinding will not be feasible in the delivery room, as the healthcare providers will use two different ventilation devices including the VN 500 Ventilator (VTV-PPV Group) and the Neopuff T-Piece (PPV Group). The outcome assessor will be unaware of the group allocation. This blinding will be maintained until the data is locked for the final analysis, which will be performed blinded to group analysis and then un-blinded.
Procedure for unblinding if needed
Members of the Data Safety Monitoring Board (DSMB) will access unblinded treatment allocations to determine causality for any severe adverse events (SAEs) or other serious trial-related events.
Data collection and management
Plans for assessment and collection of outcomes
The VOLT investigators and research nurses will collect data from maternal and infant paper or electronic medical records. Data will be entered into a REDCap™ (Vanderbilt University) electronic database, designed and managed at the University of Alberta. REDCap is a secure, web-based application that supports data capture for research studies, including database management, survey design, and audit trails to ensure data integrity.
Plans to promote participant retention and complete follow-up
We are anticipating a <5% loss to follow-up until hospital discharge. The center has conducted more than 20 neonatal trials in the delivery room with lost-to-follow-up rates for the primary outcome of <5%.
Data management
VOLT investigators and research nurses will collect maternal and infant data from paper or electronic records and enter it into REDCap™ (Vanderbilt University), a secure, web-based research database designed and managed by the University of Alberta (38, 39).
Confidentiality
Participant data will be handled in compliance with applicable data protection and privacy regulations. All data will be securely stored, with electronic records accessible only to authorized research team members via password protection. Data will be de-identified, and participant anonymity will be maintained in all scientific publications and presentations.
Biological specimens
There will be no biological specimens collected.
Statistical methods
Statistical methods for primary and secondary outcomes
WCHRI will handle, verify, and analyze VOLT-trial data, with statistical methods aligned to standard randomized trial practices. Results will be reported in compliance with CONSORT guidelines.
The primary analysis will be conducted using an “intention-to-treat” approach. The primary analysis will focus on feasibility defined as percentage (75% or greater) of eligible participants (=infants requiring PPV) who have the intervention performed correctly without protocol deviation (=cross over to control group when randomized to VTV-group). Analysis of secondary outcomes will include the above-mentioned secondary outcomes using descriptive statistics. Summary statistics will be presented for baseline and clinical characteristics; continuous data by mean, two-sided 95%CI of the mean, standard deviation, median, interquartile range (first and third quartiles), minimum and maximum. Categorical data will be presented by absolute and relative frequencies. The clinical characteristics and outcome parameters will be compared using Student's t-test for parametric and Mann–Whitney U-test for nonparametric comparisons of continuous variables, and χ2 for categorical variables. The analysis will be 2-sided and p-value <0.05 will be considered statistically significant.
Interim safety analyses
The DSMB will conduct one interim safety analyses throughout the trial to assess in-hospital mortality and SAEs after 24 (50%) infants recruited.
Methods for additional analyses (e.g., subgroup analyses)
At the end of each intervention, the clinician's workload will be assessed using the Surgery Task Load Index (SURG-TLX)-questionnaire (40). The SURG-TLX- questionnaire is a multidimensional workload measure to assess the impact of six various sources of stress on the perceived demands of trained healthcare professionals. These six aspects are then combined into a total workload score.
The SURG-TLX- questionnaire will assess:
1. Task complexity (How complex was the procedure?)
2. Physical demands (How physically fatiguing was the procedure?)
3. Mental demands (How mentally fatiguing was the procedure?)
4. Distraction (How distracting was the operating environment?)
5. Situational stress (How anxious did you feel while performing the procedure?)
6. Temporal demands (How hurried or rushed was the pace of the procedure?)
Furthermore, clinicians will be asked about their experience of using VTV-PPV by completing a short survey to solicit their feedback on switching between CPAP and PPV with the ventilator, not directly manipulating airway pressures during VTV-PPV, and performing ventilation corrective steps during VTV-PPV.
Analysis population and missing data
There will be no analysis for missing data will be reported and sensitivity analyses considered.
Plans to give access to the full protocol, participant level-data and statistical code
Trial information is publicly available on ClinicalTrials.gov (NCT05144724) and the Research4Babies website. The protocol will be shared and submitted for publication, and the de-identified VOLT dataset will be released 6 months after the primary outcome is published; data requests can be emailed toZ2Vvcmcuc2NobW9lbHplckBtZS5jb20=and will be decided by the VOLT Trial Steering Committee.
Oversight and monitoring
Composition of the coordinating center and trial steering committee
The trial management team is based at the Royal Alexandra Hospital, Edmonton, Canada, includes the Principal Investigators (GMS), and the Trial coordinators (Caroline Fray and Erin Perla), and meets weekly (Table 2).
Trial steering committee
The Trial Steering Committee detailed below meets approximately quarterly, chaired by GMS.
Composition of the data monitoring committee, its role, and reporting structure
The DSMB, composed of three independent members (Chair, neonatal clinician, and biostatistician), is guided by a pre-finalized Charter to safeguard participants, monitor trial conduct, advise investigators, and oversee interim safety reviews. It will meet about every six months and for interim safety analyses, with no pre-specified stopping criteria (Table 3).
Adverse event reporting and harms
Safety reporting from the VOLT-Trial will follow standards from the University of Alberta Human Research Ethics Board and the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (34).
Pre-defined SAE are:
- Death in the delivery room
- Death in the Neonatal Intensive Care Unit
Auditing
The Ethics Committee will review trial conduct annually, while the independent DSMB will meet every six months for trial oversight and interim safety analyses. The Trial Steering Committee will convene quarterly to monitor conduct throughout the study.
Plans for communicating important protocol amendments to relevant parties
Since trial initiation, there have been no major protocol amendments. Minor modifications have been submitted for approval to the relevant ethics committees and subsequently distributed and communicated to all participating sites.
Dissemination plans
Trial results
Trial results will be shared at national and international conferences, submitted to high-impact journals, and disseminated through media and social media. A lay summary, developed in collaboration with the Canadian Premature Babies Foundation, will be provided to all participating families.
Discussion
The VOLT-trial will evaluate the feasibility of using VTV-PPV in the delivery room to reduce brain injury and improve outcomes in extremely preterm infants. Findings will address evidence gaps in initial ventilation at birth and inform a future large-scale definitive randomized trial.
Trial status
The current Protocol version is 3.5, dated October 4, 2022. Recruitment began in October 2024 at Royal Alexandra Hospital, Edmonton. Recruitment is expected to be completed in 2026 with results expected in 2027.
Author contributions
BL: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Validation, Writing – review & editing, Visualization. MY: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Validation, Writing – review & editing. PD: Conceptualization, Investigation, Methodology, Validation, Writing – review & editing, Data curation, Visualization. GP: Conceptualization, Data curation, Investigation, Methodology, Validation, Visualization, Writing – review & editing, Project administration. MD: Conceptualization, Methodology, Project administration, Validation, Visualization, Writing – review & editing. AM: Conceptualization, Methodology, Project administration, Validation, Visualization, Writing – review & editing. GS: Conceptualization, Methodology, Project administration, Validation, Writing – review & editing, Data curation, Formal analysis, Funding acquisition, Investigation, Resources, Writing – original draft.
Funding
The author(s) declared that financial support was received for this work and/or its publication. We would like to thank the Women's and Children Research Institute, University of Alberta for funding the trial via the Innovation Grant scheme.
Acknowledgments
We wish to thank the babies and their families that are taking part in the VOLT-trial as well as all healthcare professionals who work so hard on the trial.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
WCHRI, women and children's health research institute; PPV, positive pressure ventilation; VT, tidal volume; PIP, peak inflation pressure; VTV, volume-targeted ventilation; RFM, respiratory function monitor; HIE, hypoxic-ischemic encephalopathy; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; NICU, neonatal intensive care unit; ROP, retinopathy of prematurity; SAE, severe adverse event; DSMB, data safety monitoring board; SURG-TLX, surgery task load index; VOLT, volume targeted mask ventilation versus pressure ventilation in preterm infants trial.
References
1. Aziz K, Lee HC, Escobedo MB, Hoover AV, Kamath-Rayne BD, Kapadia VS, et al. Part 5: neonatal resuscitation: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. (2020) 142:S524–50. doi: 10.1161/cir.0000000000000902
2. Wyckoff MH, Wyllie J, Aziz K, Almeida Md, Fabres J, Fawke J, et al. Neonatal life support: 2020 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation. (2020) 142:S185–221. doi: 10.1161/cir.0000000000000895
3. Madar J, Roehr CC, Ainsworth S, Ersdal H, Morley C, Rüdiger M, et al. European resuscitation council guidelines 2021: newborn resuscitation and support of transition of infants at birth. Resuscitation. (2021) 161:291–326. doi: 10.1016/j.resuscitation.2021.02.014
4. Schmölzer GM, Pas At, Davis PG, Morley CJ. Reducing lung injury during neonatal resuscitation of preterm infants. J Pediatr. (2008) 153:741–5. doi: 10.1016/j.jpeds.2008.08.016
5. Schmölzer GM, Dawson JA, Kamlin COF, O’Donnell CP, Morley CJ, Davis PG. Airway obstruction and gas leak during mask ventilation of preterm infants in the delivery room. Arch Dis Child Fetal Neonatal Ed. (2011) 96:F254. doi: 10.1136/adc.2010.191171
6. Poulton DA, Schmölzer GM, Morley CJ, Davis PG. Assessment of chest rise during mask ventilation of preterm infants in the delivery room. Resuscitation. (2011) 82:175–9. doi: 10.1016/j.resuscitation.2010.10.012
7. Brugada M, Schilleman K, Witlox RSGM, Walther FJ, Pas At. Variability in the assessment of “adequate” chest excursion during simulated neonatal resuscitation. Neonatology. (2011) 100:99–104. doi: 10.1159/000322009
8. Vilstrup CT, Björklund LJ, Werner O, Larsson A. Lung volumes and pressure-volume relations of the respiratory system in small ventilated neonates with severe respiratory distress syndrome. Pediatr Res. (1996) 39:127–33. doi: 10.1203/00006450-199601000-00019
9. Schmölzer GM, Wong C, Dawson JA, Kamlin COF, Donath S, Hooper SB, et al. Respiratory function monitor guidance of mask ventilation in the delivery room: a feasibility study. J Pediatr. (2012) 160:377–81.e2. doi: 10.1016/j.jpeds.2011.09.017
10. Sarrato GZ, Luna MS, Sarrato SZ, Pérez AP, Chamorro IP, Cano JMB. New strategies of pulmonary protection of preterm infants in the delivery room with the respiratory function monitoring. Am J Perinatol. (2019) 36:1368–76. doi: 10.1055/s-0038-1676828
11. Zanten Hv, Kuypers KLAM, Zwet Ev, Vonderen Jv, Kamlin COF, Springer L, et al. A multi-centre randomised controlled trial of respiratory function monitoring during stabilisation of very preterm infants at birth. Resuscitation. (2021) 167:317–25. doi: 10.1016/j.resuscitation.2021.07.012
12. Schmölzer GM, Kamlin OCOF, O’Donnell CPF, Dawson JA, Morley CJ, Davis PG. Assessment of tidal volume and gas leak during mask ventilation of preterm infants in the delivery room. Arch Dis Child Fetal Neonatal Ed. (2010) 95:F393. doi: 10.1136/adc.2009.174003
13. Dawson JA, Schmölzer GM, Kamlin COF, Pas At, O’Donnell CPF, Donath SM, et al. Oxygenation with T-piece versus self-inflating bag for ventilation of extremely preterm infants at birth: a randomized controlled trial. J Pediatr. (2011) 158:912–18.e2. doi: 10.1016/j.jpeds.2010.12.003
14. Hernandez LA, Peevy KJ, Moise AA, Parker JC. Chest wall restriction limits high airway pressure-induced lung injury in young rabbits. J Appl Physiol. (1989) 66:2364–8. doi: 10.1152/jappl.1989.66.5.2364
15. Dreyfuss D, Saumon G. Barotrauma is volutrauma, but which volume is the one responsible? Intens Care Med. (1992) 18:139–41. doi: 10.1007/bf01709236
16. Dreyfuss D, Basset G, Soler P, Saumon G. Intermittent positive-pressure hyperventilation with high inflation pressures produces pulmonary microvascular injury in rats. Am Rev Respir Dis. (1985) 132:880–4. doi: 10.1164/arrd.1985.132.4.880
17. Barton SK, Tolcos M, Miller SL, Roehr C-C, Schmölzer GM, Davis PG, et al. Unraveling the links between the initiation of ventilation and brain injury in preterm infants. Front Pediatr. (2015) 3:97. doi: 10.3389/fped.2015.00097
18. Barton SK, Tolcos M, Miller SL, Roehr C-C, Schmölzer GM, Moss TJM, et al. Ventilation-induced brain injury in preterm neonates: a review of potential therapies. Neonatology. (2016) 110:155–62. doi: 10.1159/000444918
19. Polglase GR, Miller SL, Barton SK, Baburamani AA, Wong FY, Aridas JDS, et al. Initiation of resuscitation with high tidal volumes causes cerebral hemodynamic disturbance, brain inflammation and injury in preterm lambs. PLoS One. (2012) 7:e39535. doi: 10.1371/journal.pone.0039535
20. Skiöld B, Wu Q, Hooper SB, Davis PG, McIntyre R, Tolcos M, et al. Early detection of ventilation-induced brain injury using magnetic resonance spectroscopy and diffusion tensor imaging: an in vivo study in preterm lambs. PLoS One. (2014) 9:e95804. doi: 10.1371/journal.pone.0095804
21. Björklund LJ, Vilstrup CT, Larsson A, Svenningsen NW, Werner O. Changes in lung volume and static expiratory pressure-volume diagram after surfactant rescue treatment of neonates with established respiratory distress syndrome. Am J Respir Crit Care Med. (1996) 154:918–23. doi: 10.1164/ajrccm.154.4.8887586
22. Hillman NH, Kramer BW, Moss TJM, Kallapur SG, Bachurski C, Pillow JJ, et al. Brief, large tidal volume ventilation initiates lung injury and a systemic response in fetal sheep. Am J Respir Crit Care Med. (2007) 176:575–81. doi: 10.1164/rccm.200701-051-c
23. Mian Q, Cheung P-Y, O’Reilly M, Barton SK, Polglase GR, Schmölzer GM. Impact of delivered tidal volume on the occurrence of intraventricular haemorrhage in preterm infants during positive pressure ventilation in the delivery room. Arch Dis Child Fetal Neonatal Ed. (2019) 104:F57. doi: 10.1136/archdischild-2017-313864
24. Milner A, Murthy V, Bhat P, Fox GF, Campbell ME, Milner AD, et al. Evaluation of respiratory function monitoring at the resuscitation of prematurely born infants. Eur J Pediatr. (2015) 174:205–8. doi: 10.1007/s00431-014-2379-2
25. Medeiros Sd, Mangat A, Polglase GR, Sarrato GZ, Davis PG, Schmölzer GM. Respiratory function monitoring to improve the outcomes following neonatal resuscitation: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. (2022) 107:589–96. doi: 10.1136/archdischild-2021-323017
26. Klingenberg C, Wheeler KI, Davis PG, Morley CJ. A practical guide to neonatal volume guarantee ventilation. J Perinatol. (2011) 31:575–85. doi: 10.1038/jp.2011.98
27. Klingenberg C, Wheeler KI, McCallion N, Morley CJ, Davis PG. Volume-targeted versus pressure-limited ventilation in neonates. Cochrane Database Syst Rev. (2017) 2017:CD003666. doi: 10.1002/14651858.cd003666.pub4
28. Kaam Av, Rimensberger PC, Borensztajn D, Jaegere APD, Group NS. Ventilation practices in the neonatal intensive care unit: a cross-sectional study. J Pediatr. (2010) 157:767–71.e1–3. doi: 10.1016/j.jpeds.2010.05.043
29. Tracy MB, Klimek J, Coughtrey H, Shingde V, Ponnampalam G, Hinder M, et al. Ventilator-delivered mask ventilation compared with three standard methods of mask ventilation in a manikin model. Arch Dis Child Fetal Neonatal Ed. (2011) 96:F201. doi: 10.1136/adc.2009.169730
30. Jain D, D’Ugard C, Aguilar A, Moral Td, Bancalari E, Claure N. Use of a mechanical ventilator with respiratory function monitoring provides more consistent ventilation during simulated neonatal resuscitation. Neonatology. (2020) 117:151–8. doi: 10.1159/000503257
31. Menakaya J, Andersen C, Chirla D, Wolfe R, Watkins A. A randomised comparison of resuscitation with an anaesthetic rebreathing circuit or an infant ventilator in very preterm infants. Arch Dis Child Fetal Neonatal Ed. (2004) 89:F494. doi: 10.1136/adc.2003.033340
32. Boer Md, Houtlosser M, Foglia EE, Davis PG, Kaam AHv, Kamlin COF, et al. Deferred consent for the enrolment of neonates in delivery room studies: strengthening the approach. Arch Dis Child Fetal Neonatal Ed. (2019) 104:F348. doi: 10.1136/archdischild-2018-316461
33. Katheria A, Schmölzer GM, Janvier A, Kapadia V, Saugstad OD, Vento M, et al. A narrative review of the rationale for conducting neonatal emergency studies with a waived or deferred consent approach. Neonatology. (2023) 120:344–52. doi: 10.1159/000530257
34. Ethics G of C Interagency Advisory Panel on Research. Interagency Advisory Panel on Research Ethics. TCPS 2: The Interagency Advisory Panel on Research Ethics (PRE) Available online at: https://www.pre.ethics.gc.ca/eng/policy-politique/initiatives/tcps2-eptc2/Default/ (Accessed September 01, 2025).
35. Papile L-A, Burstein J, Burstein J, Burstein R, Burstein R, Koffler H, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. (1978) 92:529–34. doi: 10.1016/s0022-3476(78)80282-0
36. Prematurity IC for the C of R of. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. (2005) 123:991–9. doi: 10.1001/archopht.123.7.991
37. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. (1978) 187:1–7. doi: 10.1097/00000658-197801000-00001
38. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. (2019) 95:103208. doi: 10.1016/j.jbi.2019.103208
39. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. (2009) 42:377–81. doi: 10.1016/j.jbi.2008.08.010
Keywords: infant, extremely preterm, neonatal intensive care, delivery room, respiratory function tests, neonatal mortality
Citation: Law BHY, Yaskina M, Davis PG, Polglase G, Dunn M, Mukerji A and Schmölzer GM (2026) Study protocol for the volume targeted mask ventilation versus pressure ventilation in preterm infants—the VOLT-trial. Front. Pediatr. 13:1743460. doi: 10.3389/fped.2025.1743460
Received: 10 November 2025; Revised: 23 November 2025;
Accepted: 3 December 2025;
Published: 6 January 2026.
Edited by:
Qiuping Li, Bayi Children’s Hospital, ChinaReviewed by:
Lingyue Gong, Rush University Medical Center, Chicago, United StatesDushyant Batra, Nottingham University Hospitals NHS Trust, United Kingdom
Copyright: © 2026 Law, Yaskina, Davis, Polglase, Dunn, Mukerji and Schmölzer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Georg M. Schmölzer, Z2Vvcmcuc2NobW9lbHplckBtZS5jb20=
Maryna Yaskina3